🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

COVID-19 #vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems ow.ly/XRwu50G18jk Alfred Kim (moving to Bluesky as alhkim) @WUSTLMed UCSF School of Medicine @WUSTL_Rheum; @WUSM_Pathology; @IBDWUSTL; @WUGastro; @WashUID; WashU Medicine Neurology; WashU Medicine Genetics; @WUSM_MolMicro

Finally out our 1st COVaRiPAD manuscript Annals of Int Med acpjournals.org/doi/10.7326/M2… Started as email convo in Novmbr 2020 Alfred Kim (moving to Bluesky as alhkim) @TheBcellArtist Michael Paley, M.D., Ph.D. (moving to @Bluesky) Matthew Ciorba MD Wooseob Kim grew into COVaRiPAD funded Helmsley Charitable Trust collaborators WashU Medicine Neurology & UCSF Rheumatology as Alfred Kim (moving to Bluesky as alhkim) tweets 👇🏼

(1/2) Some great news for our #autoimmune patients! Check out Alfred Kim (moving to Bluesky as alhkim) interview with KMOV about the “COVaRiPAD” study results that were published. We are so proud of this paper and the huge effort of the 60+ people involved in its creation. @WUGastro WashU Medicine Neurology COVaRiPAD

Link to paper: ow.ly/XRwu50G18jk Link to brief interview: kmov.com/news/those-imm… #SARSCoV2 #vaccine #antibodies @WUDeptMedicine WashU Medicine Division of Physician-Scientists Annals of Int Med

All star team: Alfred Kim (moving to Bluesky as alhkim) @TheBcellArtist Parakkal Deepak MD, MS, FACG Wooseob Kim Michael Paley, M.D., Ph.D. (moving to @Bluesky) Jane O’Halloran Rachel Presti Sean P.J. Whelan @sechahiin Gregory Wu Willie Buscher Matthew Ciorba MD Lianne Monica Yang Mary NAkamura @patti_katz Kim Taylor Jonathan Graf Mehrdad Matloubian

Plus too many more to name. We’d also like to thank our wonderful participants that volunteered their time (and blood) to help us with this project!

Really appreciate Annika Merrilees for highlighting our initial analyses from the COVaRiPAD study in St. Louis Post-Dispatch. And truly thank Melinda Freeman, one of our participants in the study for providing her thoughts also. stltoday.com/lifestyles/hea…

NEW PREPRINT FROM TEAM #COVaRiPAD: under the leadership of msdiamondlab & Rita Chen, those on TNFi monotherapy at higher risk of poor neutralization responses to B.1.617.2 (delta) variant at 3 & 5 mths post-vax, w/ poor Fc effector fxn capacity. 1/ medrxiv.org/content/10.110…

Will provide an update tomorrow, including some interesting delta cross-neutralization data, for those interested: Abst # 0457 Plenary I 11:45 AM meet.acrconvergence.org/meetings/YQMF9… And gotta thank Michael Paley, M.D., Ph.D. (moving to @Bluesky) for introducing UpSet plots to me. #ACR21 #ACRambassador

Some more #COVaRiPAD work presented at #ACR21: Monica Yang, Abs # 0113 Epidemiology & Public Health Poster I: COVID-19 & Vaccination 11/6, 0730 EDT Niti Pawar, Abs # 1590 Patient Outcomes, Preferences, & Attitudes IV: COVID-19 11/9, 0730 EST #ACRambassador

Now out in Med by Cell Press from team COVaRiPAD: Reduced Ab activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNFα inhibitors (cell.com/med/fulltext/S…). Thread below for details, but there's 1 new piece of data you'll want to see...

COVaRiPAD New Med by Cell Press 👉 reduced neutraliz. abs with TNFi esp. against B.1.617.2 Delta virus 👉 Neut titers of all TNFi pts below threshold for antibody-mediated protection @5 months 👉 3rd mRNA vaccine dose boosted neut antibody titers > 16-fold. sciencedirect.com/science/articl…

We have a long way to go but we won’t stop advocating for our patients. Just like our very own Alfred Kim (moving to Bluesky as alhkim) who was interviewed for this article! Thank you, Ed Yong is not here for writing this important piece! theatlantic.com/health/archive… @WUDeptMedicine #immunocompromised #COVIDvaccine

Thrilled to present our analysis of the relationship between the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine in immunosuppressed patients with chronic inflammatory disease in the COVaRiPAD cohort, now out in ACR_Journals: onlinelibrary.wiley.com/doi/10.1002/ac…

Thank you, KSDK News, for sharing the experience of one of many patients that are #immunocompromised ! Alfred Kim (moving to Bluesky as alhkim) #COVID19 ksdk.com/article/news/h…

On behalf of the co-authors, I am delighted to present our observations from the #COVaRiPAD cohort examining longitudinal changes in patient-reported outcomes following SARS-CoV-2 vaccination in the immunosuppressed: onlinelibrary.wiley.com/doi/10.1002/ac…

Congrats to Niti Pawar who led the effort (as a UCSF School of Medicine med student!) on another #COVaRiPAD manuscript! Job well done by the entire team!

Another manuscript on longitudinal changes in PROS using PROMIS following SARS-CoV-2 vaccination, published from our group at the COVaRiPAD cohort funded by Helmsley Charitable Trust 🧵 by 1st author Niti Pawar UCSF School of Medicine 👇🏼

Great talk by Alfred Kim (moving to Bluesky as alhkim) today at the @WUSTL_Rheum Translational Research Conference on immunosupression and SARS-CoV-2 vaccination! Great work again by all of the collaborators (too many to tag)! @IbdWustl @WashUID @WUSTLneurosci @wusm_pathology UCSF Rheumatology #Research #COVID19